This site is intended for health professionals only

At the heart of general practice since 1960

NICE should speak up on rosiglitazone

I am very pleased with the new drug guidelines from NICE ('Gliptins given key diabetes role', pulsetoday.co.uk/news).

The institute is to be congratulated in devising an algorithm for health professionals in treatment of type 2 diabetes, with recommendations for both glitazones and gliptins second-line where there are concerns regarding hypoglycaemia.

It is a shame, however, that NICE was unable to give a clear lead on the continuing controversy of cardiovascular safety of rosiglitazone, which is tarnishing the image of the glitazones as a class.

From Professor Anthony Barnett, professor of medicine and honorary consultant physician at the University of Birmingham

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say